Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation

Annals of Nuclear Medicine

Volumn 26, Issue 4, 2012, Pages 311-318

  Hong, Chae Moon ^a   Ahn, Byeong Cheol ^a   Park, Ji Young ^a   Jeong, Shin Young ^a   Lee, Sang Woo ^a   Lee, Jaetae ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Early recurrence; Papillary thyroid cancer; Prognosis; Radioactive iodine ablation; Resection margin involvement

Indexed keywords

IODINE 123; IODINE 131;

ABLATION THERAPY; ADULT; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HIGH DOSE RADIOACTIVE IODINE ABLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; NECK DISSECTION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; THYROID CANCER; THYROIDECTOMY;

ABLATION TECHNIQUES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROGNOSIS; RADIATION DOSAGE; RECURRENCE; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84862800288     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0574-7     Document Type: Review

References (25)

1. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784-91.
2. Wang TS, Roman SA, Sosa JA. Differentiated thyroid cancer: an update. Curr Opin Oncol. 2011;23:7-12.
3. Engroff SL, Coletti D. Bisphosphonate related osteonecrosis of the palate: report of a case managed with free tissue transfer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:580-2.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 1998;83:2638-48. (Pubitemid 29019586)
5. Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol). 2010;22:395-404.
6. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
7. Farahati J, Reiners C, Stuschke M, Muller SP, Stuben G, Sauerwein W, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer. 1996;77:172-80. (Pubitemid 26002754)
8. Kim TH, Chung KW, Lee YJ, Park CS, Lee EK, Kim TS, et al. The effect of external beam radiotherapy volume on locoregional control in patients with locoregionally advanced or recurrent nonanaplastic thyroid cancer. Radiat Oncol. 2010;5:69.
9. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer. 1998;82:375-88. (Pubitemid 28060256)
10. Edge SB, Greene FL, Trotti A, Fritz AG, Compton CC, Byrd DR, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
11. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol. 2008;97:712-6. (Pubitemid 351812974)
12. David LS, Mark JL, Ang KK, William HM, David IR, Anesa A, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys. 2009;74:1083-91.
13. Passler C, Scheuba C, Prager G, Kaczirek K, Kaserer K, Zettinig G, et al. Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region. Endocr Relat Cancer. 2004;11:131-9. (Pubitemid 38419728)
14. Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol. 2005;63:418-27. (Pubitemid 41442336)
15. Gonzalez HE, Cruz F, O'Brien A, Goni I, Leon A, Claure R, et al. Impact of preoperative ultrasonographic staging of the neck in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1258-62. (Pubitemid 350294256)
16. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946-54.
17. Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim E-K. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. Am J Roentgenol. 2009;193:871-8.
18. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-63. (Pubitemid 32374886)
19. Wilson PC, Millar BM, Brierley JD. The management of advanced thyroid cancer. Clin Oncol (R Coll Radiol). 2004;16:561-8. (Pubitemid 39517665)
20. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80:1488-92.
21. Roelants V, Nayer PD, Bouckaert A, Beckers C. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:722-7. (Pubitemid 27356849)
22. Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery. 1999;126:13-9. (Pubitemid 29340686)
23. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, et al. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2005;90:1440-5.
24. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-91. (Pubitemid 18017100)
25. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. J Nucl Med. 2004;45:988-94. (Pubitemid 47611686)